Biotransformation of furosemide in kidney transplant patients
dc.contributor.author | Smith, David E. | en_US |
dc.contributor.author | Benet, Leslie Z. | en_US |
dc.date.accessioned | 2006-09-11T18:01:32Z | |
dc.date.available | 2006-09-11T18:01:32Z | |
dc.date.issued | 1983-11 | en_US |
dc.identifier.citation | Smith, D. E.; Benet, L. Z.; (1983). "Biotransformation of furosemide in kidney transplant patients." European Journal of Clinical Pharmacology 24(6): 787-790. <http://hdl.handle.net/2027.42/46639> | en_US |
dc.identifier.issn | 0031-6970 | en_US |
dc.identifier.issn | 1432-1041 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/46639 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=6350024&dopt=citation | en_US |
dc.description.abstract | The metabolic fate of furosemide was studied in kidney transplant patients after oral and intravenous administration of the diuretic at therapeutic doses. Serial urine samples were collected over a 24 h period and furosemide was analyzed by a specific high performance liquid chromatographic method using fluorescence detection. We found no evidence of the putative furosemide metabolite, 2-amino-4-chloro-5-sulfamoylanthranilic acid (CSA), in any of the samples analyzed. The amount of furosemide excreted as the glucuronide metabolite accounted for 8% of the available dose, whether administered orally or by intravenous infusion. In addition, the significant positive correlation observed between the percent of the available dose excreted as furosemide glucuronide and the renal clearance of furosemide ( r =0.581, p <0.02) suggests that the glucuronidation process for furosemide may be occurring in the kidney. Furosemide and its glucuronide metabolite accounted for only 45% of the intravenous dose recovered in the urine. Biliary excretion of unchanged furosemide and/or furosemide glucuronide into the feces probably accounts for the remainder of the dose not recovered. | en_US |
dc.format.extent | 350072 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Springer-Verlag | en_US |
dc.subject.other | Biomedicine | en_US |
dc.subject.other | Biliary Excretion | en_US |
dc.subject.other | Furosemide Glucuronide | en_US |
dc.subject.other | Metabolism | en_US |
dc.subject.other | Pharmacology/Toxicology | en_US |
dc.subject.other | Furosemide | en_US |
dc.subject.other | Kidney Transplant Patients | en_US |
dc.subject.other | Renal Function | en_US |
dc.title | Biotransformation of furosemide in kidney transplant patients | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Pharmacy, School of Pharmacy, University of California, San Francisco, California, USA; College of Pharmacy, The University of Michigan, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationother | Department of Pharmacy, School of Pharmacy, University of California, San Francisco, California, USA | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 6350024 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/46639/1/228_2004_Article_BF00607088.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/BF00607088 | en_US |
dc.identifier.source | European Journal of Clinical Pharmacology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.